MedTrace Logo

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

NCT06093230 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-23

No results posted yet for this study

Summary

Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical medication plans for patients with liver function impairment;

Conditions

  • Subjects With Liver Function Injury
  • Normal Liver Function Subject

Interventions

DRUG

Deuremidevir Hydrobromide Tablets

JT001 single dose, 0.3g

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • Shanghai Vinnerna Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huiyu Lan, Project Director · Shanghai Vinnerna Biosciences Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2023-08-18
Completion
2023-08-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093230 on ClinicalTrials.gov